NYSE - Nasdaq Real Time Price USD

Becton, Dickinson and Company (BDX)

Compare
239.48 -2.03 (-0.84%)
As of 2:01 PM EDT. Market Open.
Loading Chart for BDX
DELL
  • Previous Close 241.51
  • Open 241.55
  • Bid 239.40 x 800
  • Ask 239.51 x 900
  • Day's Range 238.02 - 242.29
  • 52 Week Range 218.75 - 269.52
  • Volume 473,185
  • Avg. Volume 1,370,423
  • Market Cap (intraday) 69.22B
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 47.90
  • EPS (TTM) 5.00
  • Earnings Date Nov 7, 2024
  • Forward Dividend & Yield 3.80 (1.57%)
  • Ex-Dividend Date Sep 9, 2024
  • 1y Target Est 276.27

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

www.bd.com

70,000

Full Time Employees

September 30

Fiscal Year Ends

Recent News: BDX

View More

Performance Overview: BDX

Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BDX
0.59%
S&P 500
20.25%

1-Year Return

BDX
5.86%
S&P 500
33.76%

3-Year Return

BDX
1.91%
S&P 500
31.57%

5-Year Return

BDX
6.23%
S&P 500
93.66%

Compare To: BDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BDX

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    69.81B

  • Enterprise Value

    83.82B

  • Trailing P/E

    48.40

  • Forward P/E

    17.39

  • PEG Ratio (5yr expected)

    1.11

  • Price/Sales (ttm)

    3.55

  • Price/Book (mrq)

    2.70

  • Enterprise Value/Revenue

    4.23

  • Enterprise Value/EBITDA

    18.86

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.13%

  • Return on Assets (ttm)

    3.25%

  • Return on Equity (ttm)

    5.63%

  • Revenue (ttm)

    19.83B

  • Net Income Avi to Common (ttm)

    1.46B

  • Diluted EPS (ttm)

    5.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.31B

  • Total Debt/Equity (mrq)

    74.70%

  • Levered Free Cash Flow (ttm)

    4.43B

Research Analysis: BDX

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

240.00
276.27 Average
239.48 Current
324.12 High
 

Company Insights: BDX

Research Reports: BDX

View More
  • Large Cap US Pick List - September 2024

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

     
  • BD's Alaris Trajectory Is Solid, While China Remains a Headwind

    Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

    Rating
    Price Target
     
  • Monday Tee Up: Here Comes Walmart The focus this week flips back to inflation

    Monday Tee Up: Here Comes Walmart The focus this week flips back to inflation and the state of the consumer. Key inflation data will come out as will perhaps the most-telling earnings report related to the consumer -- Walmart. Wall Street is wondering if the Fed has been right on interest rates and can still achieve a soft landing and avoid recession. Last week, the Dow Jones Industrial Average ended down 0.6%, the S&P 500 lost 0.4%, and the Nasdaq fell 0.2%. Year to date, the Dow is higher by 5%, the S&P is up 12%, and the Nasdaq is higher by 12%. On the economic calendar, the big day is Wednesday, when inflation data comes out in the form of CPI. In June, CPI posted at 3.0%. Core CPI was 3.1%. We see July matching those rates. On Tuesday, wholesale inflation will grab the headlines when PPI is updated. On Thursday, Retail Sales, Industrial Production, and Capacity Utilization all will be released, and on Friday, Consumer Sentiment and Housing Starts come out. The earnings calendar is winding down but some big releases are due in this week. On Tuesday, Home Depot and On Holding report. On Wednesday, Cisco and UBS Group. And on Thursday, Walmart, Applied Materials, Alibaba, and Deere. Earnings are coming in 12.4% higher this quarter than a year ago (this after some 91% of S&P 500 companies have reported). Expectations were for 8%-12% earnings growth for 2Q. This follows 8% growth in 1Q and 10% in 4Q23. Last week, mortgage rates fell a big 26 basis points (bps) to 6.47% for the average 30-year fixed-rate mortgage. Gas prices fell four cents to $3.45 per gallon for the average price of regular gas. The Atlanta Fed GDPNow indicator is forecasting for 3Q and calls for expansion of 2.9%. The Cleveland Fed CPINow indicator forecasts 2.74% for August CPI. Looking ahead, the next Fed rate decision is on September 18, with odds at 100% for a rate cut. Of that, 51% expect a 25-bps cut and 49% expect a 50-bps cut. That data is according to the CME FedWatch Tool. There are then two more Fed rate meetings this year, on November 7, two days after the U.S. presidential election, and December 18.

     
  • We see GLP-1 autoinjectors driving growth

    Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.

    Rating
    Price Target
     

People Also Watch